A newly recognised form of dementia is reshaping how clinicians and researchers understand cognitive decline in older age. Known as LATE — Limbic-predominant Age-related TDP-43 Encephalopathy — the condition has gained attention in recent years for closely mimicking Alzheimer’s disease while following a distinct biological pathway. Growing evidence suggests that many diagnoses previously attributed to Alzheimer’s may, in fact, relate to LATE, particularly among the oldest patients.
Although still relatively unfamiliar outside specialist circles, LATE is increasingly discussed in medical literature in countries such as the United States, where large-scale neuropathological studies have helped clarify its prevalence and characteristics. Its recognition marks an important step towards improving diagnostic accuracy and tailoring future treatments for dementia.
An under-recognised but widespread condition
LATE primarily affects memory and tends to develop later in life. Epidemiological studies indicate that it may be present in roughly one third of individuals aged over 85, and in around 10% of those aged 65 and above. These figures suggest that a substantial number of elderly patients diagnosed with Alzheimer’s disease may actually be experiencing a different neurodegenerative process.
Neurologists specialising in cognitive disorders have reported that a notable proportion of patients referred with presumed Alzheimer’s show patterns more consistent with LATE when assessed in detail. This overlap has contributed to years of diagnostic uncertainty, largely because the two conditions share similar early symptoms, including forgetfulness and word-finding difficulties.
Distinct biology behind similar symptoms
Despite their clinical resemblance, LATE and Alzheimer’s disease differ significantly at the molecular level. Alzheimer’s disease is characterised by the accumulation of amyloid-beta plaques and tau tangles in the brain. LATE, by contrast, is associated with abnormal deposits of the TDP-43 protein, which disrupt normal neuronal function, particularly in limbic regions involved in memory.
Researchers have observed that when Alzheimer’s pathology and LATE coexist — a scenario not uncommon in older populations — cognitive decline tends to be more rapid and severe than in either condition alone. Conversely, cases where LATE occurs without Alzheimer’s pathology often progress more slowly and remain largely confined to memory impairment.
Advances in diagnosis and clinical assessment
The growing recognition of LATE has been driven largely by post-mortem brain studies and advances in neuroimaging. One of the most consistent findings is pronounced shrinkage of the hippocampus, a brain structure essential for learning and memory, which can be even more marked than that typically seen in Alzheimer’s disease.
In current clinical practice, diagnosing LATE involves a process of exclusion and careful evaluation. Brain imaging, biomarker tests designed to detect amyloid pathology, and detailed cognitive assessments are combined to build a more accurate picture. The absence of amyloid plaques, alongside advanced age at symptom onset and memory-dominant impairment, can point clinicians towards LATE rather than Alzheimer’s.
This distinction is clinically relevant, as patients with LATE alone are unlikely to benefit from existing Alzheimer’s medications, which are designed to target amyloid-related mechanisms.
Implications for treatment and research
At present, there is no therapy specifically approved for LATE. However, recognition of the condition has opened new avenues for research. In the United States, for example, clinical trials are exploring whether drugs used for other cardiovascular or neurological indications might help protect brain tissue and slow hippocampal atrophy associated with TDP-43 pathology.
Experts believe that acknowledging LATE may also help explain why many Alzheimer’s treatments have delivered only modest benefits in clinical trials. If a significant proportion of participants had undiagnosed LATE, this could dilute observed treatment effects and complicate interpretation of results.
A shift in understanding dementia in ageing societies
As populations age worldwide, including in high-income countries with advanced healthcare systems, accurately distinguishing between different causes of dementia is becoming increasingly important. The identification of LATE represents a shift towards a more nuanced understanding of cognitive decline in later life.
While much remains to be learned, the growing body of evidence suggests that improved recognition of LATE could lead to more precise diagnoses, better patient counselling and, ultimately, more targeted therapeutic strategies. In this sense, LATE is not merely a new diagnostic label, but a reminder of the biological diversity underlying dementia in older adults.